In 2023, Caroline Baumal, M.D. earned $1.20M in total compensation at Apellis Pharmaceuticals, Inc., including $450.00K salary, $100.00K bonus and $600.00K in stock. Most recently acquired 39,594 shares in Jan 2025. Currently holds stock worth $2.20M. 2+ years at the helm of Apellis Pharmaceuticals, Inc..
Compensation History
Annual executive compensation data for Caroline Baumal, M.D., including salary, bonuses, and stock awards.
Year
2023
Total Compensation
$1.20M
Salary
$450.00K
Bonus
$100.00K
Other
$50.00K
Salary
$450.00KBoard Justification
The compensation philosophy is designed to align the CEO's pay with company performance, ensuring that a significant portion of compensation is performance-based and linked to the company's success in achieving its strategic goals.
Bonus
$100.00KBoard Justification
The bonus is based on the achievement of specific performance metrics set by the board, including revenue targets and operational milestones for the fiscal year 2023.
Other Compensation
$50.00KBoard Justification
Other compensation includes health benefits, retirement contributions, and other perquisites provided to the CEO.
Restricted Stock
Board Justification
The vested stock consists of performance-based restricted stock units (RSUs) that were granted in prior years and vested in 2023 based on the achievement of performance goals.
Performance Metrics
Performance metrics include revenue growth, operational efficiency, and successful product launches.
Caroline Baumal, M.D.
CEO of Apellis Pharmaceuticals, Inc.
Field of Expertise
Healthcare & Life Sciences - Medicine
Sector of Economy
Healthcare
CEO of Apellis Pharmaceuticals, Inc. for
2 years 11 months (Jan 2023 - Present)
Previous Experience
Chief Medical Officer at Apellis Pharmaceuticals, Inc.
Other Apellis Pharmaceuticals, Inc. CEOs
Holdings
Track Caroline Baumal, M.D.'s stock holdings and portfolio value over time.
Total Stock Sold
$319.35K
$319.35K
7,420 APLS shares
What if they kept their stock?
If Caroline Baumal, M.D. didn't sell their stock, today they would have:
Extra APLS7,420 shares worth $175.33K.
This is -45.1% and $144.02K less than what they got when they sold the stock.
Insider Trading
Caroline Baumal, M.D.'s recent stock transactions, purchases, and sales filed with the SEC.
39,594 shares
APLS
Jan 17, 2025
Received
$55.51K
APLS at $29.96/share
Jan 17, 2025
Sale
$95.21K
APLS at $33.81/share
Jan 6, 2025
Sale
25,445 shares
APLS
Jan 16, 2024
Received
$165.21K
APLS at $60.05/share
Jan 4, 2024
Sale
35,549 shares
APLS
Jan 3, 2023
Received
Rivals
Compare Caroline Baumal, M.D. with competitor CEOs and industry peers.